Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: Toxicity data from the UKALL14 trial

Leukemia

Volumn 31, Issue 1, 2017, Pages 58-64

  Patel, B ^a   Kirkwood, A A ^b   Dey, A ^b   Marks, D I ^c   McMillan, A K ^d   Menne, T F ^e   Micklewright, L ^b   Patrick, P ^b   Purnell, S ^a   Rowntree, C J ^f   Smith, P ^b   Fielding, A K ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^e NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARAGINASE MACROGOL; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DEXAMETHASONE; IMATINIB; METHOTREXATE; RITUXIMAB; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; ASPARAGINASE; MACROGOL DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPOALBUMINEMIA; INDUCTION CHEMOTHERAPY; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PANCREATITIS; PH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; AGE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; SEPSIS; TOXIC HEPATITIS;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHEMICAL AND DRUG INDUCED LIVER INJURY; HUMANS; INDUCTION CHEMOTHERAPY; MIDDLE AGED; PHILADELPHIA CHROMOSOME; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEPSIS;

EID: 84986537214     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.219     Document Type: Article

References (24)

1. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E 3rd, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983; 43: 5601-5607
2. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002; 99: 1986-1994
3. Seibel NL. Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology Am Soc Hematol Educ Program 2008, 374-380
4. Avramis VI, Spence SA. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol 2007; 29: 239-247
5. Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM. Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). J Pediatr Hematol Oncol 2011; 33: 610-616
6. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 7161-7167
7. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780-1786
8. Douer D. Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Pract Res Clin Haematol 2008; 21: 647-658
9. Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007; 109: 2744-2750
10. Stock W, Douer D, Deangelo DJ, Arellano M, Advani A, Damon L et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 2011; 52: 2237-2253
11. Wetzler M, Sanford BL, Kurtzberg J, Deoliveira D, Frankel SR, Powell BL et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia-Cancer and Leukemia Group B Study 9511. Blood 2007; 109: 4164-4167
12. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106: 3760-3767
13. Fabry U, Korholz D, Jurgens H, Gobel U, Wahn V. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children-evidence of a complement-mediated mechanism. Pediatr Res 1985; 19: 400-408
14. DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 2015; 29: 526-534
15. Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774-780
16. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004; 18: 2032-2035
17. Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 2007; 48: 254-261
18. Stock W, La M, Sanford B, Bloomfield C, Vardiman J, Gaynon P et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112: 1646-1654
19. Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol 2012; 157: 463-471
20. Douer D, Aldoss I, Lunning MA, Burke PW, Ramezani L, Mark L et al. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol 2014; 32: 905-911
21. Goekbuget N. PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003. ASH Annu Meeting Abstr 2010; 116: 494
22. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27: 911-918
23. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109: 3676-3678
24. Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011; 118: 6521-6528.